Danaher (DHR) 주식 개요
Danaher Corporation은 미국, 중국 및 전 세계에서 전문, 의료, 연구 및 산업 제품 및 서비스를 설계, 제조 및 판매합니다. 자세히 보기
DHR Community Fair Values
Create NarrativeSee what 134 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Danaher Corporation 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$211.50 |
| 52주 최고가 | US$242.80 |
| 52주 최저가 | US$160.93 |
| 베타 | 0.80 |
| 1개월 변동 | 5.17% |
| 3개월 변동 | 22.02% |
| 1년 변동 | 0.047% |
| 3년 변동 | -17.01% |
| 5년 변동 | -33.80% |
| IPO 이후 변동 | 23,752.00% |
최근 뉴스 및 업데이트
Seeking Alpha • Aug 14
Danaher: 2027 Growth Reacceleration Should Drive Upside
Summary Danaher is rated a Buy, with revenue growth expected to accelerate in 2027 as respiratory headwinds fade and bioprocessing shipments recover. DHR’s valuation is reasonable, trading at a 12% discount to its five-year average P/E, supported by strong recurring revenues and operational excellence. Life Sciences segment shows robust recovery, with 5.5% core growth and margin expansion, driven by improved pharma spending and biotech funding. Bioprocessing order delays are temporary, with over $100 million in revenue shifting to 2027, positioning DHR for future upside. Read the full article on Seeking Alpha
내러티브 업데이트 • Jul 23
DHR: Bioprocess Recovery And Diagnostics Expansion Will Support Premium Multiple
Danaher’s analyst price target is being reset modestly lower toward about $230, as analysts factor in recent bioprocessing misses, a higher assumed discount rate, and a lower future P/E multiple, even while keeping broadly constructive views on the core life sciences and diagnostics franchises. Analyst Commentary Recent Street research around Danaher highlights a mix of optimism about the long term potential of its life sciences and diagnostics businesses and concern about near term execution, particularly in bioprocessing.Recent updates
Seeking Alpha • Aug 14
Danaher: 2027 Growth Reacceleration Should Drive Upside
Summary Danaher is rated a Buy, with revenue growth expected to accelerate in 2027 as respiratory headwinds fade and bioprocessing shipments recover. DHR’s valuation is reasonable, trading at a 12% discount to its five-year average P/E, supported by strong recurring revenues and operational excellence. Life Sciences segment shows robust recovery, with 5.5% core growth and margin expansion, driven by improved pharma spending and biotech funding. Bioprocessing order delays are temporary, with over $100 million in revenue shifting to 2027, positioning DHR for future upside. Read the full article on Seeking Alpha내러티브 업데이트 • Jul 23
DHR: Bioprocess Recovery And Diagnostics Expansion Will Support Premium Multiple
Danaher’s analyst price target is being reset modestly lower toward about $230, as analysts factor in recent bioprocessing misses, a higher assumed discount rate, and a lower future P/E multiple, even while keeping broadly constructive views on the core life sciences and diagnostics franchises. Analyst Commentary Recent Street research around Danaher highlights a mix of optimism about the long term potential of its life sciences and diagnostics businesses and concern about near term execution, particularly in bioprocessing.내러티브 업데이트 • Jun 26
DHR: Bioprocess Recovery And Masimo Integration Will Support Premium Multiple
Danaher’s analyst price target has been reduced by about $5 to $242, as analysts factor in a slightly higher discount rate, a more conservative profit margin, and updated views on life science tools demand that balance cautious sector sentiment with selective signs of recovery. Analyst Commentary Recent research around Danaher points to a mixed setup, with some analysts focusing on recovery potential in life science tools and bioprocessing, and others highlighting valuation questions and business complexity.내러티브 업데이트 • May 19
DHR: Bioprocess Recovery And Masimo Deal Set To Support Premium Multiple
Analysts have trimmed the implied fair value for Danaher by about $2 to roughly $248 per share, as they balance slightly higher long term growth and margin expectations with a lower assumed P/E multiple, evolving views on bioprocess recovery, and recent price target changes across the Street. Analyst Commentary Recent Street commentary around Danaher reflects a mixed but engaged view, with several firms adjusting price targets and reassessing how quickly the company can execute on its bioprocess ambitions and broader portfolio moves.내러티브 업데이트 • May 02
DHR: Masimo Cash Acquisition Will Support Premium Future Earnings Multiple
Danaher’s updated analyst price target moves lower by about $8 per share to roughly $250, as analysts factor in more conservative assumptions for growth, profitability and future P/E multiples following a recent series of mostly downward target revisions across the Street. Analyst Commentary Recent research on Danaher reflects a mixed but generally cautious tone, with several price target cuts offset by one modest increase and a change in rating context at another company linked to Danaher’s pending acquisition activity.내러티브 업데이트 • Apr 16
DHR: Masimo Cash Deal Will Support Premium Future Earnings Multiple
Danaher’s analyst price target has been reset from about $264.91 to $257.73, as analysts factor in updated assumptions around profit margins, revenue growth, discount rates and future P/E, alongside mixed recent research that includes both target raises and cuts, as well as the planned Masimo acquisition. Analyst Commentary Recent research on Danaher reflects a split view, with some firms raising their price targets and others trimming them, while the planned Masimo acquisition sits at the center of many discussions about valuation and execution risk.내러티브 업데이트 • Apr 01
DHR: Cash Deal For Masimo Will Support Premium Future Earnings Multiple
Analysts have nudged Danaher’s price targets higher by low double digit dollar amounts, pointing to updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the key drivers behind the revised dollar values. Analyst Commentary Recent research has focused on how Danaher’s valuation reflects expectations for future execution, especially in light of the planned Masimo acquisition and refreshed targets across the life science tools peer group.내러티브 업데이트 • Mar 18
DHR: Cash Acquisition Will Support Re Rating And Premium Earnings Multiple
Analysts have nudged their price targets on Danaher higher by a few dollars into the mid $260s, citing a series of upward target revisions across the Street and support from the announced Masimo acquisition at $180 per share in cash. Analyst Commentary Recent research around Danaher has centered on the Masimo acquisition agreement at $180 per share in cash and a cluster of higher price targets that place the stock in the mid $260s to around $270.내러티브 업데이트 • Mar 04
DHR: Masimo Cash Deal Will Support Re Rating And Premium Multiple
The analyst price target for Danaher has moved higher by a mid single digit dollar amount, reflecting updated assumptions for slightly stronger revenue growth and margins, alongside recent Street research that raised targets following the Masimo acquisition announcement and sector wide target adjustments. Analyst Commentary Recent Street research around Danaher reflects a mix of optimism on the Masimo acquisition and valuation, alongside a more cautious stance on deal terms and execution risk.내러티브 업데이트 • Feb 17
DHR: Masimo Deal And Higher Future P/E Will Support Premium Multiple
Danaher’s updated analyst price target edges slightly lower to about $265, as analysts balance modest tweaks to revenue growth, profit margin and P/E assumptions with a broadly supportive run of recent target increases across the Street. Analyst Commentary Recent Street research on Danaher is clustered around higher price targets, with several bullish analysts lifting their numbers by single digit to low double digit dollar amounts.내러티브 업데이트 • Feb 03
DHR: Higher Future P/E Assumptions Will Support Premium Multiple Through Soft 2026 Outlook
Analysts have nudged their average price target for Danaher higher, with our fair value estimate moving from US$261.50 to about US$265.23. This change is supported by a modestly higher assumed future P/E multiple and by Street research that has generally lifted targets in the life science tools sector.내러티브 업데이트 • Jan 19
DHR: Share Repurchases And Soft 2026 Outlook Will Support Premium Multiple
Analysts have nudged their price targets on Danaher higher, reflected in a fair value update from US$259.23 to US$261.50, citing refreshed views on revenue growth, profit margins, and future P/E expectations in recent research. Analyst Commentary Recent price target moves on Danaher point to refreshed views on how the company could execute on growth plans, manage profitability, and justify its current P/E profile.내러티브 업데이트 • Jan 05
DHR: Share Repurchases And Diagnostics Resilience Will Support Premium Multiple
Analysts have made a modest upward adjustment to their fair value estimate for Danaher to about US$259 from about US$258, reflecting slightly higher assumed profit margins and P/E, even as they highlight tempered expectations for 2025 and 2026 growth, ongoing uncertainty in China, and questions around how durable diagnostics demand will be. Analyst Commentary Analysts are split on Danaher, with some focusing on the valuation premium and others on the company’s ability to eventually reconnect with its historical growth profile.내러티브 업데이트 • Dec 19
DHR: Share Repurchases Will Support Premium Multiple As Life Sciences Demand Recovers
Analysts modestly raised their blended fair value estimate for Danaher to about $258 from roughly $256, reflecting slightly lower discount rate and higher future multiple assumptions, even as they trim official price targets toward $220 amid ongoing uncertainty around the pace of life sciences and diagnostics recovery. Analyst Commentary Analysts broadly agree that Danaher's premium valuation assumes a reacceleration of growth across life sciences and diagnostics, but they remain divided on how quickly fundamentals will normalize versus the lingering headwinds in key end markets.내러티브 업데이트 • Dec 04
DHR: Share Repurchases Will Support Premium Multiple Despite Slower Recovery Uncertainty
Danaher's fair value estimate has been nudged slightly higher to approximately $255.67 from about $254.20, as analysts balance still premium valuations and tempered growth expectations with signs of stabilization in key Life Sciences and Diagnostics markets. Analyst Commentary Recent Street research reflects a more balanced, wait and see stance on Danaher as investors weigh premium valuation levels against a slower growth trajectory and a gradual recovery in key end markets.내러티브 업데이트 • Nov 20
DHR: Share Repurchases And Improving Profit Margins Will Drive Renewed Upside
Danaher's fair value estimate has edged slightly lower to $254.20 from $254.40, as analysts cite ongoing uncertainty in growth outlooks and mixed sector momentum. Analyst Commentary Recent analyst reports on Danaher reveal a mix of optimism around the company’s long-term positioning and concerns about near-term growth visibility and sector headwinds.내러티브 업데이트 • Nov 04
DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds
Danaher’s fair value estimate has increased to $254.40 from $247.30. This reflects analysts’ view that while growth forecasts are now more gradual and discount rates slightly higher, the stock’s premium valuation still prices in a slow recovery and ongoing sector uncertainties.내러티브 업데이트 • Oct 21
Analyst Commentary Highlights Mixed Sentiment and Minor Valuation Adjustments for Danaher
Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.내러티브 업데이트 • Sep 11
Advanced Diagnostics And Personalized Therapies Will Expand Global Markets
Danaher’s consensus price target saw a marginal downward revision to $244.50 as analysts incorporate more conservative near-term estimates amid continued sector weakness and tempered recovery expectations, despite steady long-term fundamentals. Analyst Commentary Bearish analysts are lowering price targets due to "more realistic" multiples and sector-wide weakness in Life Sciences Tools and Diagnostics, with a cautious view on near-term healthcare stock performance.Seeking Alpha • Mar 31
Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Summary Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins face short-term pressure from China's VBP initiative, but cost-cutting measures and operational efficiency should drive long-term margin expansion. The stock is undervalued compared to historical levels, trading at a discount to its average forward P/E over the last five years. I maintain a buy rating on DHR stock due to its strong long-term growth prospects and attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Mar 22
Danaher: Near 5-Year Low Is A Great Entry Point
Summary Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechnology, life sciences, and diagnostics, with robust profitability and free cash flow. Growth catalysts include advancements in bioprocessing, molecular diagnostics, and neurodegenerative disease detection, with expected EPS growth of 10%-13% annually over the next three years. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
Danaher: Self-Inflicted Pessimism?
Summary Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company’s strategic capital allocation, including share buybacks and acquisitions, suggests management is positioning for long-term value creation, despite short-term pessimism. Danaher’s bioprocessing segment shows consistent growth, and the upcoming patent cliff is expected to provide significant tailwinds, boosting demand for their life science equipment. Valuation analysis indicates the stock is currently undervalued, with potential for significant upside as market conditions improve and growth returns, making it a buy. Read the full article on Seeking Alpha주주 수익률
| DHR | US Life Sciences | US 시장 | |
|---|---|---|---|
| 7D | 2.8% | 2.6% | -0.8% |
| 1Y | 0.05% | 23.0% | 20.5% |
수익률 대 산업: DHR은 지난 1년 동안 23%의 수익을 기록한 US Life Sciences 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: DHR은 지난 1년 동안 20.5%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| DHR volatility | |
|---|---|
| DHR Average Weekly Movement | 5.7% |
| Life Sciences Industry Average Movement | 8.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: DHR는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: DHR의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1969 | 59,000 | Rainer Blair | www.danaher.com |
Danaher Corporation은 미국, 중국 및 전 세계에서 전문, 의료, 연구 및 산업 제품 및 서비스를 설계, 제조 및 판매합니다. 이 회사는 생명공학, 생명과학 및 진단 부문을 통해 운영됩니다. 생명공학 부문은 치료제 개발 및 제조를 발전, 가속화, 통합하는 기술, 소모품, 서비스, 솔루션, 세포주 및 세포 배양 배지 개발 서비스, 세포 배양 배지, 제조용 공정 액체 및 버퍼, 크로마토그래피 수지, 여과 기술, 무균 충전 마감재 등을 제공합니다; 전체 제조 제품군의 설계 및 설치, 실험실 여과, 분리 및 정제, 실험실 규모의 단백질 정제 및 분석 도구, 진단 및 분석 개발을 위한 시약, 멤브레인 및 서비스, 헬스케어 여과 솔루션과 같은 일회용 하드웨어, 소모품 및 서비스.
Danaher Corporation 기초 지표 요약
| DHR 기초 통계 | |
|---|---|
| 시가총액 | US$140.30b |
| 순이익 (TTM) | US$3.99b |
| 매출 (TTM) | US$25.11b |
37.3x
주가수익비율(P/E)5.9x
주가매출비율(P/S)DHR는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| DHR 손익계산서 (TTM) | |
|---|---|
| 매출 | US$25.11b |
| 매출원가 | US$10.36b |
| 총이익 | US$14.75b |
| 기타 비용 | US$10.76b |
| 순이익 | US$3.99b |
최근 보고된 실적
Jun 26, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 5.68 |
| 총이익률 | 58.75% |
| 순이익률 | 15.89% |
| 부채/자본 비율 | 50.5% |
DHR의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
0.8%
현재 배당 수익률26%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/19 04:25 |
| 종가 | 2026/08/19 00:00 |
| 수익 | 2026/06/26 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Danaher Corporation는 48명의 분석가가 다루고 있습니다. 이 중 23명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| John Eade | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |